—
C+
C+ The full Closelooknet — membership. Open the C+ overview

BridgeBio Pharma Inc (BBIO) — Technical state

As of 2026-11-10 — re-computed nightly across the coverage universe. Closelooknet diary readings, not advice.

The Closelooknet read

  • Closelooknet score: 36 out of 100 (momentum 55 · quality 21 · valuation 11), as of 2026-11-11.
  • Signal: Recovery attempt under the 200-day — Trades +12.7% vs the 50-day and +8.2% vs the 200-day average, 15.8% below the 52-week high and +26.8% off the 52-week low; a death cross printed 18 sessions ago. Computed from daily closes. (as of 2026-11-10)
  • Trend: BridgeBio Pharma Inc trades 12.7% above its 50-day and 8.2% above its 200-day moving average. (as of 2026-11-10)

BridgeBio Pharma develops medicines for genetic diseases. It sells Attruby, an oral stabiliser for transthyretin-mediated cardiomyopathy, and Fosdenopterin under the NULIBRY brand for molybdenum cofactor deficiency.

The full read — the desk's view, the earnings record, peers and the company snapshot — is on the BBIO overview. Agents can buy the score depth per call over HTTP 402 — see the catalogue. Research diary readings, not advice.

Recovery attempt under the 200-day

Trades +12.7% vs the 50-day and +8.2% vs the 200-day average, 15.8% below the 52-week high and +26.8% off the 52-week low; a death cross printed 18 sessions ago. Computed from daily closes.

The moving-average stack

Continue: the BBIO chart & overview · quality & forensics · the earnings record · the signal board

FAQ · from the current data · as of 2026-11-10

Quick answers

What is the current Closelooknet signal on BBIO?

Recovery attempt under the 200-day — Trades +12.7% vs the 50-day and +8.2% vs the 200-day average, 15.8% below the 52-week high and +26.8% off the 52-week low; a death cross printed 18 sessions ago. Computed from daily closes. As of 2026-11-10; the signal board re-computes across the coverage universe nightly. A research diary reading, not advice.

Is BBIO above its 50-day and 200-day moving averages?

As of 2026-11-10, BridgeBio Pharma Inc trades +12.7% above its 50-day and +8.2% above its 200-day average, with the 20-day +10.5% away.

How far is BBIO from its 52-week high?

15.8% below the 52-week high and 26.8% above the 52-week low, as of 2026-11-10.

Related in the Closelooknet universe

then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.